269,95€ plus VAT
This test detects both the early marker and the late marker, IgM/IgG antibodies in whole blood samples or simply with a finger prick like glucose tests.
Out of stock
BIOCREDIT COVID-19 lgG/lgM Manual
PDF-Document [437.1 KB]
CE Dokument COVID-19 lgG lgM
CE DoC_BIOCREDIT COVID-19 IgG+IgM Duo.pdf
PDF-Document [12.6 KB]
EU Produkt Zertifikat COVID-19 lgG/lgM Duo
RapiGEN Certificate of EU product notification.pdf
PDF-Document [382.0 KB]
RapiGEN, Inc., South Korea, has developed one of the first immunoassays for the diagnosis of COVID-19 infection.
The BIOCREDIT COVID-19 IgG+ IgM DUO One Step Rapid Test is a lateral flow immunoassay for the simultaneous detection and differentiation of IgG and IgM anti-COVID-19 in whole human blood, serum or plasma.
It is intended to be used by professionals as a screen test and as a supplement in the diagnosis of COVID-19 virus infection.
The BIOCREDIT COVID-19 IgG+IgM DUO One Step Rapid Test has been evaluated and compared to a gold standard test using clinical samples. Results show a degree of concordance of >90%.
BIOCREDIT Coronavirus Onme Step Rapid Test Kit COVID-19 antibody IgG + IgM DUO– Pack 25 test
Biocredit Covid-19 One Step Rapid Test lgG+LgM DUO has developed one of the first immunoassays for the diagnosis of COVID-19 infection.
This test detects both the early marker and the late marker, IgM/IgG antibodies in whole blood samples.
Can be used in symptomatic or asymptomatic patients.
Applications of Biocredit Coronavirus Test Kit COVID-19 antibody IgG+IgM DUO
Main applications of antibody detection during COVID-19:
Interpretation of Results
A total of three detection lines are possible, the control line © appears when the sample is correct.
1 | IgG and IgM Positive:
The colored line in the control line region © appears and two colored lines should appear in test line regions G and M (G and M). The color intensities of the lines do not have to match. The result is positive for IgG & IgM antibodies and is indicative of secondary COVID-19 infection.
2 | IgG Positive:
The colored line in the control line region © appears and a colored line appears in test line region G (G). The result is positive for COVID-19 specific-IgG and is probably indicative of secondary COVID-19 infection.
3 | IgM Positive:
The colored line in the control line region © appears and a colored line appears in test line region M (M). The result is positive for COVID-19 virus specific-IgM antibodies and is indicative of primary COVID-19 infection.
4 | Negative result:
One red line „C“
IgM appears first after infection with the virus and then IgG in the middle and late stages of infection
IgM/IgG antibody test can determine if a patient is infected “recently 2019-nCoV”
It is widely known that IgM provides the first line of defense during viral infections, followed by adaption generation, high IgG affinity response for long-term immunity and immune memory.
Therefore, the test of COVID-19 IgM and IgG antibodies is an effective method for rapid diagnosis of COVID-19 infection.
In addition, detection of IgM antibodies against COVID-19 tends to indicate recent exposure to COVID-19, while detection of COVID-19 IgG antibodies indicates a later stage of infection. Thus, this combined antibody test could also provide information on the stage of infection.
Manufacturer: RapiGEN Inc., 2F, 25, Heungan-daero, Gunpo-si, Gyeonggi-do 15809, Republic of Korea
European Representative: MT Promedt Consulting GmbH, Altenhofstrasse. 80, 66386 St. Ingbert, Germany
Distribution Pharmacies: Weko Pharma GmbH, Hochwaldblick 3–4, 54331 Pellingen
This offer is exclusive to commercial customers with qualified personel. This includes: Doctors, outpatient and inpatient facilities in health care, e.g. physiotherapy clinics, wholesalers and pharmacies, health authorities of the federal government, the federal states, the municipalities and municipal associations, blood donation services, pharmaceutical companies, advisory and test facilities for at risk people.
You confirm that you are placing the order for commercial/medical purposes and that you are handing over the products to the appropriate qualified personel.
Please note that due to high demand, delivery may be take longer than expected.
The regular delivery time is 3–5 work days.
269,95€ plus VAT
GENEDIA W COVID-19 Ag device is a chromatographic immunoassay for the qualitative detection of specific antigens to COVID-19 present in human nasopharyngeal swab and sputum. (20 Tests/Kit)
269,95€ plus VAT
The Rapid Biocredit Antigen Test from RapiGEN, South Korea, offers a fast and reliable solution for detection of SARS-CoV-2 antigen in remote applications and without the need for complex laboratory instruments at efficient cost and convenience.